Real-World Dosing Patterns and Outcomes Among Patients With Chronic Lymphocytic Leukemia With or Without Dose Adjustment of First-Line Ibrutinib

被引：0
|
作者：
Rogers, Kerry [1 ]
Lu, Xiaoxiao [2 ]
Emond, Bruno [3 ]
Ding, Zhijie [2 ]
Lefebvre, Patrick [3 ]
Lafeuille, Marie-Helene [3 ]
Mavani, Heena [2 ]
Qureshi, Zaina [2 ]
Ghosh, Nilanjan [4 ]
机构：
[1] Ohio State Univ, Columbus, OH 43210 USA
[2] Janssen Sci Affairs, Horsham, PA USA
[3] Anal Grp Inc, Montreal, PQ, Canada
[4] Levine Canc Inst, Charlotte, NC USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
CLL; dose adjustment; real-world dosing; ibrutinib; chronic lymphocytic leukemia; outcomes;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CLL-586
引用
收藏
页码：S330 / S330
页数：1
相关论文
共 50 条
  • [41] Real-world time to discontinuation of first-line venetoclax plus binutuzumab in chronic lymphocytic leukemia/small lymphocytic lymphoma
    Lu, Xiaoxiao
    Emond, Bruno
    Qureshi, Zaina P.
    Wu, Linda H.
    Forbes, Shaun P.
    Hilts, Annalise
    Liu, Stephanie
    Lafeuille, Marie-Helene
    Lefebvre, Patrick
    Huang, Qing
    Rogers, Kerry A.
    CURRENT MEDICAL RESEARCH AND OPINION, 2023,
  • [42] Clinical Outcomes Among Real-World Patients with Chronic Lymphocytic Leukemia (CLL) Initiating First-Line Ibrutinib or Chemoimmunotherapy (CIT) Stratified By Risk Status: Results from a US Retrospective Chart Review Study
    Qing Huang
    Deering, Kathleen L.
    Harshaw, Qing
    Bhagnani, Tarun
    Leslie, Lori A.
    BLOOD, 2020, 136
  • [43] Real-world treatment patterns and characteristics in patients with chronic lymphocytic leukemia
    Schenkel, Brad
    Rider, Alex
    Macomson, Brian
    Hallworth, Pam
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (08)
  • [44] Real-World First-Line Treatment Patterns Among US Carcinoid Syndrome Patients
    Sun, Gordon H.
    Neary, Maureen P.
    Chang, Eunice
    Broder, Michael S.
    PANCREAS, 2015, 44 (02) : 359 - 360
  • [45] Real-World Outcomes Among 2L+Patients with Chronic Lymphocytic Leukemia (CLL) By Line of Therapy (LOT)
    Davids, Matthew S.
    Ambrose, Jacob
    De Nigris, Enrico
    Prescott, Jennifer
    Leng, Siyang
    Farooqui, Mohammed Z. H.
    Gandra, Shravanthi R.
    Zettler, Christina M.
    Fernandes, Laura L.
    Wang, Ching-Kun
    Shadman, Mazyar
    BLOOD, 2023, 142
  • [46] Time to next treatment in patients with chronic lymphocytic leukemia initiating first-line ibrutinib or acalabrutinib
    Jacobs, Ryan
    Lu, Xiaoxiao
    Emond, Bruno
    Morrison, Laura
    Kinkead, Frederic
    Lefebvre, Patrick
    Lafeuille, Marie-Helene
    Khan, Wasiulla
    Wu, Linda H.
    Qureshi, Zaina P.
    Levy, Moshe Yair
    FUTURE ONCOLOGY, 2024, 20 (01) : 39 - 53
  • [47] Real-World Treatment Patterns and Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib in the UK: A Preliminary Analysis
    Xie, Jing
    Yong, Alan
    Waweru, Catherine
    Sorof, Thuy Anh
    Goyal, Ravi K.
    Davis, Keith L.
    Follows, George
    Hillmen, Peter
    BLOOD, 2019, 134
  • [48] Real-World Patient Characteristics, Treatment Patterns, and Outcomes in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia in China: A Retrospective Analysis Using a Real-World Database
    Liu, Yin
    Chen, Yanfei
    Xiao, Yue
    Huang, Ruijian
    Jiang, Feng
    Yi, Shuhua
    Zhou, Jifang
    BLOOD, 2023, 142
  • [49] Real-world clinical outcomes in patients receiving either ibrutinib or chemoimmunotherapy (CIT) as first-line (1L) treatment for chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL): A retrospective analysis.
    Wu, Linda
    Ran, Tao
    He, Jinghua
    Panjabi, Sumeet
    Lu, Xiaoxiao
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [50] Real-world effectiveness and safety of ibrutinib in patients with chronic lymphocytic leukemia in Japan: the Orbit study
    Muta, Tsuyoshi
    Masamoto, Yosuke
    Yamamoto, Go
    Kurahashi, Shingo
    Kameoka, Yoshihiro
    Ota, Shuichi
    Matsuki, Eri
    Ozeki, Kazutaka
    Toyama, Takanori
    Takahashi, Naoki
    Kumode, Takahiro
    Aotsuka, Nobuyuki
    Yoshimura, Takuro
    Tamura, Hideto
    Omi, Ai
    Shibayama, Kazuhiro
    Watanabe, Aki
    Isobe, Yasushi
    Kojima, Kensuke
    Takizawa, Jun
    Nagai, Hirokazu
    Suzumiya, Junji
    Aoki, Sadao
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2024, : 161 - 173
12345